Current Therapies to Target HDL: Update on Clinical Trials

Current Therapies to Target HDL: Update on Clinical Trials Benjamin Ansell, MD, FACC, FACP, FNLA Professor of Medicine Div. of Gen. Internal Medicine ...
Author: Alban King
1 downloads 0 Views 622KB Size
Current Therapies to Target HDL: Update on Clinical Trials Benjamin Ansell, MD, FACC, FACP, FNLA Professor of Medicine Div. of Gen. Internal Medicine and Cardiology, Geffen School of Medicine at UCLA

Low HDL-C Is a Well-Established, Independent CHD Risk Factor: ARIC Men

Relative Risk for Incident CHD

1.2 1.0

1.0

0.8

0.8

0.6

0.6

0.4

0.4

0.2

0.2

0.0

0.0 1

2

3

Women

1.2

4

5

1

2

3

4

5

1.44 56

1.69 65

2.09 81

HDL-C Quintiles mmol/L mg/dL (median)

0.80 31

0.97 1.11 38 43

1.27 1.60 49 62

1.01 1.25 39 48

Adjusted for age and race, 12-year follow-up; N=12,339 Sharrett AR et al. Circulation 2001;104:1108-1113. Ballantyne CM. Eur Heart J Suppl. 2003;5 (Suppl D):D17-D25.

5-Year Risk of Major CVD Events (%)

HDL-C Levels and CV Events: TNT 10

Patients With LDL-C